STUDY OF THE STAINING SOLUTION MEDIATED BY THE FOLATO RECEIVER (FRD BY ITS ACRONYMS IN ENGLISH) IN THE DETECTION OF CERVICAL CANCER.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

REPEC

Registry ID

PER-047-18

Enrollment

800

Registered

2019-04-03

Start date

2019-01-01

Completion date

Unknown

Last updated

2023-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

(FRD) EPITELIAL CELL STAINING SOLUTION Type of group

NAME OF THE INTERVENTION: PLACE SOLUTION OF STAINING IN UTERINE NECK. PHARMACEUTICAL FORM AND VIA ADMINISTRATION: SOLUTION, FOLIC ACID 1% + BLUE OF METHYLENE 0.1% + ASCORBIC ACID 0.8% + HYDROXYBUTYL ACID 0.05% + ACETIC ACID 5% + SYLFOXIDE. DOSAGE: 1 ONLY DOSAGE DURATION OF TREATMENT_1 ONLY DOSE.

Eligibility

Inclusion criteria

Inclusion criteria: -MUJER BETWEEN 20-60 -DIAGNOSIS: WOMAN WHO NEEDS TO BE PERFORMED GYNECOLOGICAL PELVIC EXAMINATION FOR CERVICAL CANCER DISCARD. WOMEN WHO HAVE REGULAR CONDITIONS TO PERFORM A COLPOSCOPY. (DO NOT HAVE VAGINAL SHOWS, NO SEXUAL RELATIONS AND NOT BEING MENTRUANDO)

Exclusion criteria

Exclusion criteria: MUJERES WITH TOTAL HYSTERECTOMY. WOMEN WHO HAD CERVICAL SURGERY, INCLUDING CONIZATION, PROCEDURE OF ELECTRO SURGICAL EXCISION (LEEP, OF ITS ABBREVIATIONS IN ENGLISH) AND INFRARED RAYS. WOMEN WITH SERIOUS CERVICAL HEMORRHAGE OF CONTACT-PREGNANT WOMEN - WOMEN WITH ACUTE INFLAMMATION OF THE UTERINE NECK AND / OR THE VAGINA - WOMEN WHO WERE ALREADY DIAGNOSED WITH CONNIC2 + WOMEN WHO USE INJECTABLE OR ORAL DRUGS AGAINST CANCER

Design outcomes

Primary

Measure	Time frame
Outcome name:EXAMINATION WITH THE SPECULO GINECOLOGIA Measure:REDUCTION EVALUATION: EVALUATE THE CLINICAL PERFORMANCE OF THE MEDIATED STAINING SOLUTION BY THE FOLATO RECEIVER (FRD) IN THE DETECTION OF CERVICAL NEOPLASTIC LESIONS (NIC2 +) DURING THE EXAMINATION WITH GYNECOLOGIST SPECULO Timepoints:ANNUAL CONTROL WITH CITOLOGY	—

Secondary

Measure	Time frame
Outcome name:INDICE DE EVALUACION DE PRUEBA DE DETECCION Measure:DETECTION TEST Timepoints:HISTOPATHOLOGICAL RESULT TIME 72 HOURS	—

Countries

Georgia, Peru

Contacts

Public ContactRAUL YEPEZ

PERUVIAN CLINICAL RESEARCH S.A.C

r.yepez@pcr.pe999962145

Outcome results